Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates.

Gilchuk P, Mire CE, Geisbert JB, Agans KN, Deer DJ, Cross RW, Slaughter JC, Flyak AI, Mani J, Pauly MH, Velasco J, Whaley KJ, Zeitlin L, Geisbert TW, Crowe JE Jr.

J Infect Dis. 2018 Jul 5. doi: 10.1093/infdis/jiy295. [Epub ahead of print]

PMID:
29982718
2.

Marburg and Ravn Viruses Fail to Cause Disease in the Domestic Ferret (Mustela putorius furo).

Cross RW, Mire CE, Agans KN, Borisevich V, Fenton KA, Geisbert TW.

J Infect Dis. 2018 Jun 28. doi: 10.1093/infdis/jiy268. [Epub ahead of print]

PMID:
29955887
3.

Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates.

Woolsey C, Geisbert JB, Matassov D, Agans KN, Borisevich V, Cross RW, Deer DJ, Fenton KA, Eldridge JH, Mire CE, Geisbert TW.

J Infect Dis. 2018 Jun 25. doi: 10.1093/infdis/jiy293. [Epub ahead of print]

PMID:
29939296
4.

Correction for Olsen et al., "Polyamines and Hypusination Are Required for Ebolavirus Gene Expression and Replication".

Olsen ME, Filone CM, Rozelle D, Mire CE, Agans KN, Hensley L, Connor JH.

MBio. 2018 Jun 5;9(3). pii: e01065-18. doi: 10.1128/mBio.01065-18. No abstract available.

5.

Post-exposure treatments for Ebola and Marburg virus infections.

Cross RW, Mire CE, Feldmann H, Geisbert TW.

Nat Rev Drug Discov. 2018 May 4. doi: 10.1038/nrd.2018.73. [Epub ahead of print]

PMID:
29725132
6.

Correction: A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates.

Callendret B, Vellinga J, Wunderlich K, Rodriguez A, Steigerwald R, Dirmeier U, Cheminay C, Volkmann A, Brasel T, Carrion R, Giavedoni LD, Patterson JL, Mire CE, Geisbert TW, Hooper JW, Weijtens M, Hartkoorn-Pasma J, Custers J, Grazia Pau M, Schuitemaker H, Zahn R.

PLoS One. 2018 Apr 24;13(4):e0196546. doi: 10.1371/journal.pone.0196546. eCollection 2018.

7.

A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates.

Callendret B, Vellinga J, Wunderlich K, Rodriguez A, Steigerwald R, Dirmeier U, Cheminay C, Volkmann A, Brasel T, Carrion R, Giavedoni LD, Patterson JL, Mire CE, Geisbert TW, Hooper JW, Weijtens M, Hartkoorn-Pasma J, Custers J, Grazia Pau M, Schuitemaker H, Zahn R.

PLoS One. 2018 Feb 20;13(2):e0192312. doi: 10.1371/journal.pone.0192312. eCollection 2018. Erratum in: PLoS One. 2018 Apr 24;13(4):e0196546.

8.

Post-exposure treatments for Ebola and Marburg virus infections.

Cross RW, Mire CE, Feldmann H, Geisbert TW.

Nat Rev Drug Discov. 2018 Jun;17(6):413-434. doi: 10.1038/nrd.2017.251. Epub 2018 Jan 29. Review. Erratum in: Nat Rev Drug Discov. 2018 May 04;:.

PMID:
29375139
9.

Single Dose Trivalent Vesiculovax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.

Matassov D, Mire CE, Latham T, Geisbert JB, Xu R, Ota-Setlik A, Agans KN, Kobs DJ, Wendling MQS, Burnaugh A, Rudge TL Jr, Sabourin CL, Egan MA, Clarke DK, Geisbert TW, Eldridge JH.

J Virol. 2017 Nov 15. pii: JVI.01190-17. doi: 10.1128/JVI.01190-17. [Epub ahead of print]

10.

Transcriptome Analysis of Circulating Immune Cell Subsets Highlight the Role of Monocytes in Zaire Ebola Virus Makona Pathogenesis.

Menicucci AR, Versteeg K, Woolsey C, Mire CE, Geisbert JB, Cross RW, Agans KN, Jankeel A, Geisbert TW, Messaoudi I.

Front Immunol. 2017 Oct 26;8:1372. doi: 10.3389/fimmu.2017.01372. eCollection 2017.

11.

siRNA rescues nonhuman primates from advanced Marburg and Ravn virus disease.

Thi EP, Mire CE, Lee AC, Geisbert JB, Ursic-Bedoya R, Agans KN, Robbins M, Deer DJ, Cross RW, Kondratowicz AS, Fenton KA, MacLachlan I, Geisbert TW.

J Clin Invest. 2017 Dec 1;127(12):4437-4448. doi: 10.1172/JCI96185. Epub 2017 Nov 6.

12.

Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever.

Mire CE, Cross RW, Geisbert JB, Borisevich V, Agans KN, Deer DJ, Heinrich ML, Rowland MM, Goba A, Momoh M, Boisen ML, Grant DS, Fullah M, Khan SH, Fenton KA, Robinson JE, Branco LM, Garry RF, Geisbert TW.

Nat Med. 2017 Oct;23(10):1146-1149. doi: 10.1038/nm.4396. Epub 2017 Sep 4.

13.

Infection with the Makona variant results in a delayed and distinct host immune response compared to previous Ebola virus variants.

Versteeg K, Menicucci AR, Woolsey C, Mire CE, Geisbert JB, Cross RW, Agans KN, Jeske D, Messaoudi I, Geisbert TW.

Sci Rep. 2017 Aug 29;7(1):9730. doi: 10.1038/s41598-017-09963-y.

14.

Neutralizing the Threat: Pan-Ebolavirus Antibodies Close the Loop.

Mire CE, Geisbert TW.

Trends Mol Med. 2017 Aug;23(8):669-671. doi: 10.1016/j.molmed.2017.06.008. Epub 2017 Jul 8.

15.

Enhanced light microscopy visualization of virus particles from Zika virus to filamentous ebolaviruses.

Daaboul GG, Freedman DS, Scherr SM, Carter E, Rosca A, Bernstein D, Mire CE, Agans KN, Hoenen T, Geisbert TW, Ünlü MS, Connor JH.

PLoS One. 2017 Jun 26;12(6):e0179728. doi: 10.1371/journal.pone.0179728. eCollection 2017.

16.

Evaluation of Medical Countermeasures Against Ebolaviruses in Nonhuman Primate Models.

Mire CE, Geisbert TW.

Methods Mol Biol. 2017;1628:293-307. doi: 10.1007/978-1-4939-7116-9_24.

PMID:
28573630
17.

Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody.

Mire CE, Geisbert JB, Borisevich V, Fenton KA, Agans KN, Flyak AI, Deer DJ, Steinkellner H, Bohorov O, Bohorova N, Goodman C, Hiatt A, Kim DH, Pauly MH, Velasco J, Whaley KJ, Crowe JE Jr, Zeitlin L, Geisbert TW.

Sci Transl Med. 2017 Apr 5;9(384). pii: eaai8711. doi: 10.1126/scitranslmed.aai8711.

18.

Disposable cartridge platform for rapid detection of viral hemorrhagic fever viruses.

Scherr SM, Freedman DS, Agans KN, Rosca A, Carter E, Kuroda M, Fawcett HE, Mire CE, Geisbert TW, Ünlü MS, Connor JH.

Lab Chip. 2017 Feb 28;17(5):917-925. doi: 10.1039/c6lc01528j.

PMID:
28194457
19.

Assessment of the potential for host-targeted iminosugars UV-4 and UV-5 activity against filovirus infections in vitro and in vivo.

Warfield KL, Warren TK, Qiu X, Wells J, Mire CE, Geisbert JB, Stuthman KS, Garza NL, Van Tongeren SA, Shurtleff AC, Agans KN, Wong G, Callahan MV, Geisbert TW, Klose B, Ramstedt U, Treston AM.

Antiviral Res. 2017 Feb;138:22-31. doi: 10.1016/j.antiviral.2016.11.019. Epub 2016 Nov 28.

PMID:
27908828
20.

Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA.

Thi EP, Lee AC, Geisbert JB, Ursic-Bedoya R, Agans KN, Robbins M, Deer DJ, Fenton KA, Kondratowicz AS, MacLachlan I, Geisbert TW, Mire CE.

Nat Microbiol. 2016 Aug 22;1(10):16142. doi: 10.1038/nmicrobiol.2016.142.

21.

Molecular Diagnostic Field Test for Point-of-Care Detection of Ebola Virus Directly From Blood.

Benzine JW, Brown KM, Agans KN, Godiska R, Mire CE, Gowda K, Converse B, Geisbert TW, Mead DA, Chander Y.

J Infect Dis. 2016 Oct 15;214(suppl 3):S234-S242. Epub 2016 Sep 16.

22.

Passive Immunotherapy: Assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates.

Mire CE, Geisbert JB, Agans KN, Thi EP, Lee AC, Fenton KA, Geisbert TW.

J Infect Dis. 2016 Oct 15;214(suppl 3):S367-S374. Epub 2016 Aug 28.

23.

Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies.

Cross RW, Mire CE, Branco LM, Geisbert JB, Rowland MM, Heinrich ML, Goba A, Momoh M, Grant DS, Fullah M, Khan SH, Robinson JE, Geisbert TW, Garry RF.

Antiviral Res. 2016 Sep;133:218-222. doi: 10.1016/j.antiviral.2016.08.012. Epub 2016 Aug 13.

24.

Pathogenic Differences between Nipah Virus Bangladesh and Malaysia Strains in Primates: Implications for Antibody Therapy.

Mire CE, Satterfield BA, Geisbert JB, Agans KN, Borisevich V, Yan L, Chan YP, Cross RW, Fenton KA, Broder CC, Geisbert TW.

Sci Rep. 2016 Aug 3;6:30916. doi: 10.1038/srep30916.

25.

Polyamines and Hypusination Are Required for Ebolavirus Gene Expression and Replication.

Olsen ME, Filone CM, Rozelle D, Mire CE, Agans KN, Hensley L, Connor JH.

MBio. 2016 Jul 26;7(4). pii: e00882-16. doi: 10.1128/mBio.00882-16. Erratum in: MBio. 2018 Jun 5;9(3):.

26.

The Domestic Ferret (Mustela putorius furo) as a Lethal Infection Model for 3 Species of Ebolavirus.

Cross RW, Mire CE, Borisevich V, Geisbert JB, Fenton KA, Geisbert TW.

J Infect Dis. 2016 Aug 15;214(4):565-9. doi: 10.1093/infdis/jiw209. Epub 2016 May 24.

27.

Isolation and Characterization of a Novel Gammaherpesvirus from a Microbat Cell Line.

Shabman RS, Shrivastava S, Tsibane T, Attie O, Jayaprakash A, Mire CE, Dilley KE, Puri V, Stockwell TB, Geisbert TW, Sachidanandam R, Basler CF.

mSphere. 2016 Feb 17;1(1). pii: e00070-15. doi: 10.1128/mSphere.00070-15. eCollection 2016 Jan-Feb.

28.

Oral and Conjunctival Exposure of Nonhuman Primates to Low Doses of Ebola Makona Virus.

Mire CE, Geisbert JB, Agans KN, Deer DJ, Fenton KA, Geisbert TW.

J Infect Dis. 2016 Oct 15;214(suppl 3):S263-S267. Epub 2016 Jun 9.

29.

Nipah Virus C and W Proteins Contribute to Respiratory Disease in Ferrets.

Satterfield BA, Cross RW, Fenton KA, Borisevich V, Agans KN, Deer DJ, Graber J, Basler CF, Geisbert TW, Mire CE.

J Virol. 2016 Jun 24;90(14):6326-6343. doi: 10.1128/JVI.00215-16. Print 2016 Jul 15.

30.

Ebola virus vaccines - reality or fiction?

Mire CE, Geisbert TW, Feldmann H, Marzi A.

Expert Rev Vaccines. 2016 Nov;15(11):1421-1430. Epub 2016 May 9. Review.

31.

Single-Vector, Single-Injection Recombinant Vesicular Stomatitis Virus Vaccines Against High-Containment Viruses.

Whitt MA, Geisbert TW, Mire CE.

Methods Mol Biol. 2016;1403:295-311. doi: 10.1007/978-1-4939-3387-7_16.

PMID:
27076138
32.

Differential Regulation of Interferon Responses by Ebola and Marburg Virus VP35 Proteins.

Edwards MR, Liu G, Mire CE, Sureshchandra S, Luthra P, Yen B, Shabman RS, Leung DW, Messaoudi I, Geisbert TW, Amarasinghe GK, Basler CF.

Cell Rep. 2016 Feb 23;14(7):1632-1640. doi: 10.1016/j.celrep.2016.01.049. Epub 2016 Feb 11.

33.

The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses.

Pécheur EI, Borisevich V, Halfmann P, Morrey JD, Smee DF, Prichard M, Mire CE, Kawaoka Y, Geisbert TW, Polyak SJ.

J Virol. 2016 Jan 6;90(6):3086-92. doi: 10.1128/JVI.02077-15.

34.

Correction: Analytical Performance Characteristics of the Cepheid GeneXpert Ebola Assay for the Detection of Ebola Virus.

Pinsky BA, Sahoo MK, Sandlund J, Kleman M, Kulkarni M, Grufman P, Nygren M, Kwiatkowski R, Baron EJ, Tenover F, Denison B, Higuchi R, Van Atta R, Beer NR, Carrillo AC, Naraghi-Arani P, Mire CE, Ranadheera C, Grolla A, Lagerqvist N, Persing DH.

PLoS One. 2015 Dec 21;10(12):e0145896. doi: 10.1371/journal.pone.0145896. eCollection 2015. No abstract available.

35.

Targeting Innate Immunity for Antiviral Therapy through Small Molecule Agonists of the RLR Pathway.

Pattabhi S, Wilkins CR, Dong R, Knoll ML, Posakony J, Kaiser S, Mire CE, Wang ML, Ireton RC, Geisbert TW, Bedard KM, Iadonato SP, Loo YM, Gale M Jr.

J Virol. 2015 Dec 16;90(5):2372-87. doi: 10.1128/JVI.02202-15.

36.

Analytical Performance Characteristics of the Cepheid GeneXpert Ebola Assay for the Detection of Ebola Virus.

Pinsky BA, Sahoo MK, Sandlund J, Kleman M, Kulkarni M, Grufman P, Nygren M, Kwiatkowski R, Baron EJ, Tenover F, Denison B, Higuchi R, Van Atta R, Beer NR, Carrillo AC, Naraghi-Arani P, Mire CE, Ranadheera C, Grolla A, Lagerqvist N, Persing DH.

PLoS One. 2015 Nov 12;10(11):e0142216. doi: 10.1371/journal.pone.0142216. eCollection 2015. Erratum in: PLoS One. 2015;10(12):e0145896.

37.

Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses.

Meyer M, Garron T, Lubaki NM, Mire CE, Fenton KA, Klages C, Olinger GG, Geisbert TW, Collins PL, Bukreyev A.

J Clin Invest. 2015 Aug 3;125(8):3241-55. doi: 10.1172/JCI81532. Epub 2015 Jul 13.

38.

Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.

Matassov D, Marzi A, Latham T, Xu R, Ota-Setlik A, Feldmann F, Geisbert JB, Mire CE, Hamm S, Nowak B, Egan MA, Geisbert TW, Eldridge JH, Feldmann H, Clarke DK.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S443-51. doi: 10.1093/infdis/jiv316. Epub 2015 Jun 24.

39.

The immunomodulating V and W proteins of Nipah virus determine disease course.

Satterfield BA, Cross RW, Fenton KA, Agans KN, Basler CF, Geisbert TW, Mire CE.

Nat Commun. 2015 Jun 24;6:7483. doi: 10.1038/ncomms8483.

40.

Comparison of the Pathogenesis of the Angola and Ravn Strains of Marburg Virus in the Outbred Guinea Pig Model.

Cross RW, Fenton KA, Geisbert JB, Ebihara H, Mire CE, Geisbert TW.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S258-70. doi: 10.1093/infdis/jiv182. Epub 2015 Jun 19.

41.

Modeling the Disease Course of Zaire ebolavirus Infection in the Outbred Guinea Pig.

Cross RW, Fenton KA, Geisbert JB, Mire CE, Geisbert TW.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S305-15. doi: 10.1093/infdis/jiv237. Epub 2015 Jun 2.

PMID:
26038397
42.

A Single-Vector, Single-Injection Trivalent Filovirus Vaccine: Proof of Concept Study in Outbred Guinea Pigs.

Mire CE, Geisbert JB, Versteeg KM, Mamaeva N, Agans KN, Geisbert TW, Connor JH.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S384-8. doi: 10.1093/infdis/jiv126. Epub 2015 May 9.

43.

Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates.

Thi EP, Mire CE, Lee AC, Geisbert JB, Zhou JZ, Agans KN, Snead NM, Deer DJ, Barnard TR, Fenton KA, MacLachlan I, Geisbert TW.

Nature. 2015 May 21;521(7552):362-5. doi: 10.1038/nature14442. Epub 2015 Apr 22.

44.

Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.

Mire CE, Matassov D, Geisbert JB, Latham TE, Agans KN, Xu R, Ota-Setlik A, Egan MA, Fenton KA, Clarke DK, Eldridge JH, Geisbert TW.

Nature. 2015 Apr 30;520(7549):688-691. doi: 10.1038/nature14428. Epub 2015 Apr 8.

45.

Deep sequencing identifies noncanonical editing of Ebola and Marburg virus RNAs in infected cells.

Shabman RS, Jabado OJ, Mire CE, Stockwell TB, Edwards M, Mahajan M, Geisbert TW, Basler CF.

MBio. 2014 Nov 4;5(6):e02011. doi: 10.1128/mBio.02011-14.

46.

Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA.

Thi EP, Mire CE, Ursic-Bedoya R, Geisbert JB, Lee ACH, Agans KN, Robbins M, Deer DJ, Fenton KA, MacLachlan I, Geisbert TW.

Sci Transl Med. 2014 Aug 20;6(250):250ra116. doi: 10.1126/scitranslmed.3009706.

47.

Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody.

Geisbert TW, Mire CE, Geisbert JB, Chan YP, Agans KN, Feldmann F, Fenton KA, Zhu Z, Dimitrov DS, Scott DP, Bossart KN, Feldmann H, Broder CC.

Sci Transl Med. 2014 Jun 25;6(242):242ra82. doi: 10.1126/scitranslmed.3008929.

48.

Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates.

Mire CE, Geisbert JB, Agans KN, Satterfield BA, Versteeg KM, Fritz EA, Feldmann H, Hensley LE, Geisbert TW.

PLoS One. 2014 Apr 23;9(4):e94355. doi: 10.1371/journal.pone.0094355. eCollection 2014.

49.

The Marburg virus VP24 protein interacts with Keap1 to activate the cytoprotective antioxidant response pathway.

Edwards MR, Johnson B, Mire CE, Xu W, Shabman RS, Speller LN, Leung DW, Geisbert TW, Amarasinghe GK, Basler CF.

Cell Rep. 2014 Mar 27;6(6):1017-1025. doi: 10.1016/j.celrep.2014.01.043. Epub 2014 Mar 13.

50.

A recombinant Hendra virus G glycoprotein subunit vaccine protects nonhuman primates against Hendra virus challenge.

Mire CE, Geisbert JB, Agans KN, Feng YR, Fenton KA, Bossart KN, Yan L, Chan YP, Broder CC, Geisbert TW.

J Virol. 2014 May;88(9):4624-31. doi: 10.1128/JVI.00005-14. Epub 2014 Feb 12.

Supplemental Content

Support Center